Abstract
This study focuses on the identification of the products that are formed upon binding of therapeutically relevant platinum complexes to proteins like β-lactoglobulin A (LGA), human serum albumin (HSA), or human hemoglobin (HB). The respective proteins were incubated with the platinum-based anticancer drugs cisplatin, carboplatin, and oxaliplatin. LGA was selected as the model protein in addition to the two most abundant blood proteins HSA and HB. In case of the model protein, the effect of free thiol groups on the affinity of cisplatin, carboplatin, and oxaliplatin was investigated by means of liquid chromatography electrospray ionization time-of-flight mass spectrometry (LC/ESI-ToF-MS). The reduced form of LGA, which contains four free thiol groups more than the native LGA, shows a much higher affinity to the platinum-based drugs. By means of liquid chromatography coupled to inductively coupled plasma mass spectrometry, the reaction behavior of the platinum-based drugs towards HSA and HB was investigated under different conditions considering the chloride concentration (4 or 100 mM) and the incubation time (24 and 48 h). In case of carboplatin, less than 6 % protein-bound platinum was detected. However, both cisplatin and oxaliplatin display a high affinity to the proteins investigated. Further information was obtained by means of LC/ESI-ToF-MS. In case of oxaliplatin, the complex [Pt(DACH)]2+ (DACH = C6N2H14) was identified interacting with HSA and HB. For cisplatin, different results were observed for the two proteins. The complex [Pt(NH3)2Cl]+ interacted predominantly with HSA and [Pt(NH3)2]2+ with HB.
Similar content being viewed by others
References
Wong E, Giandomenico CM (1999) Chem Rev 99:2451–2466
O’Dwyer P, Stevenson JP, Johnson SW (1999) Clinical status of cisplatin, carboplatin and other platinum-based anticancer drugs. In: Lippert B (ed) Cisplatin, 1st edn. Wiley, Weinheim, pp 56–60
Falta T, Koellensperger G, Standler A, Buchberger W, Mader RM, Hann S (2009) J Anal Atom Spectrom 24:1336–1342
O’Dwyer PJ, Stevenson JP, Johnson SW (2000) Drugs 59(Suppl 4):19–27
Deconti RC, Toftness BR, Lange RC, Creasey WA (1973) Cancer Res 33:1310–1315
Esteban-Fernández D, Moreno-Gordaliza E, Cañas B, Palacios MA, Gómez-Gómez MM (2010) Metallomics 2:19–38
Peng J, Mandal R, Sawyer M, Li XF (2005) Clin Chem 51:2274–2281
Allain P, Heudi O, Cailleux A, Le Bouil A, Larra F, Boisdron-Celle M, Gamelin E (2000) Drug Metab Dispos 28:1379–1384
Brouwers EE, Tibben M, Rosing H, Schellens JH, Beijnen JH (2008) Mass Spectrom Rev 27:67–100
Brouwers EE, Huitema AD, Beijnen JH, Schellens JH (2008) BMC Clin Pharmacol 8:7
Himmelstein KJ, Patton TF, Belt RJ, Taylor S, Repta AJ, Sternson LA (1981) Clin Pharmacol Ther 29:658–664
Møller C, Tastesen HS, Gammelgaard B, Lambert IH, Stürup S (2010) Metallomics 2:811–818
Melvik JE, Dornish JM, Pettersen EO (1992) Brit J Cancer 66:260–265
Lohmann W, Hayen H, Karst U (2008) Anal Chem 80:9714–9719
Janzen R, Schwarzer M, Sperling M, Vogel M, Schwerdtle T, Karst U (2011) Metallomics 3:847–852
Ivanov AI, Christodoulou J, Parkinson JA, Barnham KJ, Tucker A, Woodrow J, Sadler PJ (1998) J Biol Chem 273:14721–14730
Will J, Wolters DA, Sheldrick WS (2008) ChenMedChem 3:1696–1707
Esteban-Fernández D, Montes-Bayón M, González EB, Gómez MMG, Palacios MA, Sanz-Medel A (2008) J Anal Atom Spectrom 23:378–384
Moreno-Gordaliza E, Cañas B, Palacios MA, Gómez-Gómez MM (2012) Talanta 88:599–608
Møller C, Sprenger RR, Sturup S, Hojrup P (2011) Analytical and Bioanalytical Chemistry 401:1619–1629
Joven J, Cliville X, Camps J, Espinel E, Simo J, Vilella E, Oliver A (1997) Clin Chem 43:1223–1231
Wheate NJ, Walker S, Craig GE, Oun R (2010) Dalton Trans 39:8113–8127
Webster PJ, Ng K, Snitch P, Jones SL, Amos N, Harnett PR (1995) J Oncol Pharm Pract 1:41–48
Timerbaev AR, Aleksenko KS, Polec-Pawlak K, Ruzik R, Semenova O, Hartinger CG, Oszwaldowski S, Galanski M, Jarosz M, Keppler BK (2004) Electrophoresis 25:1988–1995
Groessl M, Terenghi M, Casini A, Elviri L, Lobinski R, Dyson PJ (2010) J Anal Atom Spectrom 25:305–313
Raymond E, Chaney SG, Taamma A, Cvitkovic E (1998) Ann Oncol 9:1053–1071
Frey U, Ranford JD, Sadler PJ (1993) Inorg Chem 32:1333–1340
Heudi O, Mercier-Jobard S, Cailleux A, Allain P (1999) Biopharm Drug Dispos 20:107–116
King TP (1961) J Biol Chem 236:Pc5
Lapolla A, Fedele D, Reitano R, Arico NC, Seraglia R, Traldi P, Marotta E, Tonani R (2004) J Am Soc Mass Spectrom 15:496–509
Mandal R, Kalke R, Li XF (2004) Chem Res Toxicol 17:1391–1397
Lawn RM, Efstratiadis A, O’Connell C, Maniatis T (1980) Cell 21:647–651
Wilson JT, Wilson LB, Reddy VB, Cavallesco C, Ghosh PK, Deriel JK, Forget BG, Weissman SM (1980) J Biol Chem 255:2807–2814
Author information
Authors and Affiliations
Corresponding author
Additional information
Published in the topical collection Metallomics with guest editors Uwe Karst and Michael Sperling
Rights and permissions
About this article
Cite this article
Brauckmann, C., Wehe, C.A., Kieshauer, M. et al. The interaction of platinum-based drugs with native biologically relevant proteins. Anal Bioanal Chem 405, 1855–1864 (2013). https://doi.org/10.1007/s00216-012-6410-z
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00216-012-6410-z